These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 9128388)

  • 21. Anti-ganglioside antibody and neuropathy: review of our research.
    Yuki N
    J Peripher Nerv Syst; 1998; 3(1):3-18. PubMed ID: 10959233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Association between acute disseminated encephalomyelitis and Guillain-Barré syndrome in an adult].
    Pagano MA; Allievi A; Muñoz SA; Marroquín V; Biaggioni M; Vallejos LF
    Medicina (B Aires); 2011; 71(3):254-6. PubMed ID: 21745776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.
    Ang CW; De Klerk MA; Endtz HP; Jacobs BC; Laman JD; van der Meché FG; van Doorn PA
    Infect Immun; 2001 Apr; 69(4):2462-9. PubMed ID: 11254608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory infiltrates in the spinal cord of patients with Guillain-Barré syndrome.
    Müller HD; Beckmann A; Schröder JM
    Acta Neuropathol; 2003 Dec; 106(6):509-17. PubMed ID: 13680278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis.
    Zhang HL; Zheng XY; Zhu J
    Cytokine Growth Factor Rev; 2013 Oct; 24(5):443-53. PubMed ID: 23791985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiglycolipid antibodies in Guillain-Barré syndrome and related diseases: review of clinical features and antibody specificities.
    Ariga T; Yu RK
    J Neurosci Res; 2005 Apr; 80(1):1-17. PubMed ID: 15668908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies.
    Prendergast MM; Moran AP
    J Endotoxin Res; 2000; 6(5):341-59. PubMed ID: 11521055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside.
    Yuki N; Ang CW; Koga M; Jacobs BC; van Doorn PA; Hirata K; van der Meché FG
    Ann Neurol; 2000 Mar; 47(3):314-21. PubMed ID: 10716250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Association of IgA anti-GM1 antibody with antecedent diarrhea in patients with Guillain-Barré syndrome].
    Koga M; Yuki N; Hirata K
    Rinsho Shinkeigaku; 1997 Sep; 37(9):848-50. PubMed ID: 9431003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 3-year-old boy with Guillain-Barré syndrome and encephalitis associated with Mycoplasma pneumoniae infection.
    Hanzawa F; Fuchigami T; Ishii W; Nakajima S; Kawamura Y; Endo A; Arakawa C; Kohira R; Fujita Y; Takahashi S
    J Infect Chemother; 2014 Feb; 20(2):134-8. PubMed ID: 24462436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ataxic Guillain-Barré syndrome associated with anti-GM1b and anti-GalNAc-GD1a antibodies.
    Odaka M; Yuki N; Tatsumoto M; Tateno M; Hirata K
    J Neurol; 2004 Jan; 251(1):24-9. PubMed ID: 14999485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome.
    Kaida K; Sonoo M; Ogawa G; Kamakura K; Ueda-Sada M; Arita M; Motoyoshi K; Kusunoki S
    Neurology; 2008 Nov; 71(21):1683-90. PubMed ID: 19015484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antiganglioside antibodies in the pathogenesis of autoimmune neuropathies].
    Kusunoki S
    Rinsho Shinkeigaku; 1999 Jan; 39(1):93-5. PubMed ID: 10377820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Guillain-Barré syndrome of axonal type, Campylobacter jejuni infection and anti-ganglioside GM1 antibodies].
    Attarian S; Bonnefoi-Kyriacou B; Gayraud D; Mignard P; Boucraut J; Pouget J; Viallet F
    Rev Neurol (Paris); 1997 Apr; 153(3):205-8. PubMed ID: 9296136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GQ1b antibody testing in Guillain-Barre syndrome and variants.
    Chaudhry F; Gee KE; Vaphiades MS; Biller J; Jay W
    Semin Ophthalmol; 2006; 21(4):223-7. PubMed ID: 17182410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome.
    Wanschitz J; Maier H; Lassmann H; Budka H; Berger T
    Brain; 2003 Sep; 126(Pt 9):2034-42. PubMed ID: 12847075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-ganglioside antibodies and the presynaptic motor nerve terminal.
    Willison HJ; Plomp JJ
    Ann N Y Acad Sci; 2008; 1132():114-23. PubMed ID: 18567860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effector mechanisms of PNS demyelination in Gal-C induced-EAN].
    Saida K
    Rinsho Shinkeigaku; 1990 Dec; 30(12):1361-3. PubMed ID: 2129197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute disseminated encephalomyelitis.
    Dale RC
    Semin Pediatr Infect Dis; 2003 Apr; 14(2):90-5. PubMed ID: 12881796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Guillain-Barré syndrome; pathogenesis and treatment.
    Van Der Meché FG
    Rev Neurol (Paris); 1996 May; 152(5):355-8. PubMed ID: 8881429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.